UK markets closed
  • FTSE 100

    7,019.53
    +36.03 (+0.52%)
     
  • FTSE 250

    22,522.18
    +50.14 (+0.22%)
     
  • AIM

    1,254.25
    +6.12 (+0.49%)
     
  • GBP/EUR

    1.1538
    +0.0027 (+0.23%)
     
  • GBP/USD

    1.3842
    +0.0058 (+0.42%)
     
  • BTC-GBP

    44,605.00
    -1,396.57 (-3.04%)
     
  • CMC Crypto 200

    1,398.97
    +7.26 (+0.52%)
     
  • S&P 500

    4,185.47
    +15.05 (+0.36%)
     
  • DOW

    34,200.67
    +164.68 (+0.48%)
     
  • CRUDE OIL

    63.07
    -0.39 (-0.61%)
     
  • GOLD FUTURES

    1,777.30
    +10.50 (+0.59%)
     
  • NIKKEI 225

    29,683.37
    +40.68 (+0.14%)
     
  • HANG SENG

    28,969.71
    +176.57 (+0.61%)
     
  • DAX

    15,459.75
    +204.42 (+1.34%)
     
  • CAC 40

    6,287.07
    +52.93 (+0.85%)
     

Insights on the Krabbe Disease Treatment Global Market to 2027 - Featuring Abbott Laboratories, GlaxoSmithKline and Novartis Among Others

Research and Markets
·2-min read

Dublin, April 07, 2021 (GLOBE NEWSWIRE) -- The "Krabbe Disease Treatment - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Amid the COVID-19 crisis, the global market for Krabbe Disease Treatment estimated at US$833.8 Million in the year 2020, is projected to reach a revised size of US$1.2 Billion by 2027, growing at a CAGR of 5.6% over the analysis period 2020-2027.

Anticoagulants, one of the segments analyzed in the report, is projected to record a 5.4% CAGR and reach US$503 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Muscle Relaxants segment is readjusted to a revised 5.1% CAGR for the next 7-year period.

The U.S. Market is Estimated at $245.8 Million, While China is Forecast to Grow at 5.2% CAGR

The Krabbe Disease Treatment market in the U.S. is estimated at US$245.8 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$214.8 Million by the year 2027 trailing a CAGR of 5.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.3% and 4.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

HSCT Segment to Record 6.5% CAGR

In the global HSCT segment, USA, Canada, Japan, China and Europe will drive the 6.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$135.1 Million in the year 2020 will reach a projected size of US$210.6 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$140.3 Million by the year 2027.

Select Competitors (Total 42 Featured):

  • Abbott Laboratories

  • CENETOGENE N.V.

  • GlaxoSmithKline

  • Johnson & Johnson

  • Novartis AG

  • Pfizer

  • Sanofi-Aventis SA

  • Shire

  • Teva Pharmaceutical Industries Ltd.

  • UCB Pharmaceuticals

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

  • Total Companies Profiled: 42

For more information about this report visit https://www.researchandmarkets.com/r/udt42k

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900